Drug Profile
MDR 103
Alternative Names: MDR-103Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Medeor Therapeutics
- Class Cell therapies; Haematopoietic stem cells therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Cell replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Renal transplant rejection
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for phase-I development in Renal-transplant-rejection in USA (Parenteral, Infusion)
- 24 Apr 2019 Medeor Therapeutics plans a phase II trial in Renal transplant rejection (In adults, In the elderly) in USA (IV) (NCT03606746)
- 11 May 2017 Phase-I clinical trials in Renal transplant rejection in USA (Parenteral) (Medeor Therapeutics' website, May 2017)